The Technical Analyst
Connect Biopharma [CNTB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Connect Biopharma Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.99% $1.475
America/New_York / 8 mai 2024 @ 09:37
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 81.28 mill |
| EPS: | -1.080 |
| P/E: | -1.370 |
| Earnings Date: | Apr 16, 2024 |
| SharesOutstanding: | 55.10 mill |
| Avg Daily Volume: | 0.168 mill |
| RATING 2024-05-07 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | n/a | n/a | ||||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.370 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.23x |
| Company: PE -1.370 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.375 (-6.76%) $-0.0997 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.218 - 1.732 ( +/- 17.42%) |
| ATR Model: 14 days |
Forecast:
11:16 - $1.498
Live Trading Signals (every 1 min)
Forecast
1: 09:46 - $1.456
Forecast 2: 10:36 - $1.502
Forecast 3: 11:16 - $1.498
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.475 (-2.99% ) |
| Volume | 0.0068 mill |
| Avg. Vol. | 0.168 mill |
| % of Avg. Vol | 4.03 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CNTB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CNTB
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Latest Press Releases
2024-05-07 06:30:00 - Press Release
Connect Biopharma To Present A Late-breaking Abstract At The American Thoracic Society (ats) 2024 International Conference On The Positive Results From The Global Phase 2b Trial Of Rademikibart In Patients With Moderate-to-severe Asthma
San diego, ca and taicang, china, may 07, 2024 (globe newswire) -- connect biopharma holdings limited (nasdaq: cntb) (“connect biopharma” or the “company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from t cell-driven research, today announced data from its global phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-breaking abstract for poster presentation at the upcoming ats 2024 international meeting being held may 17-22, 2024 in san diego, ca.
2024-04-16 16:05:00 - Press Release
Connect Biopharma Reports Full Year 2023 Financial Results And Provides Business Update
San diego, ca and taicang, china, april 16, 2024 (globe newswire) -- connect biopharma holdings limited (nasdaq: cntb) (“connect biopharma,” “connect” or the “company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from t cell-driven research, today reported financial results for the year ended december 31, 2023, and provided a business update.
2024-03-19 08:30:00 - Press Release
Connect Biopharma To Participate In H.c. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
San diego and taicang, china, march 19, 2024 (globe newswire) -- connect biopharma holdings limited (nasdaq: cntb) (“connect biopharma” or the “company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from t cell-driven research, today announced that zheng wei, ph.d., co-founder and ceo, and raÚl collazo, ph.d., global head of medical affairs will participate in h.c. wainwright 2nd annual autoimmune & inflammatory disease virtual conference in a fireside chat on thursday, march 28, 2024 at 4:00 p.m. et. please see below for additional details about the event and how to request a one-on-one meeting with management.
2024-02-12 16:30:00 - Press Release
Connect Biopharma Appoints Industry Veteran James Huang To Board Of Directors
San diego, ca and taicang, china, feb. 12, 2024 (globe newswire) -- connect biopharma holdings limited (nasdaq: cntb) (“connect biopharma” or the “company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from t cell-driven research, announced today the appointment of james zuie-chin huang, m.b.a., to its board of directors effective immediately. james huang is the founder and managing partner of panacea venture, a significant shareholder of the company.
2023-12-12 06:00:00 - Press Release
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results In Adult Patients With Moderate-to-severe Persistent Asthma
San diego, ca and taicang, china, dec. 12, 2023 (globe newswire) -- connect biopharma holdings limited (nasdaq: cntb) (“connect biopharma” or the “company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from t cell-driven research, announced today positive topline results from the global phase 2b trial evaluating rademikibart efficacy and safety in adult patients with moderate-to-severe persistent asthma.
Latest News
2024-05-07 06:30:00 - GlobeNewsWire
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-breaking abstract for poster presentation at the upcoming ATS 2024 International Meeting being held May 17-22, 2024 in San Diego, CA.
2024-03-19 08:30:00 - GlobeNewsWire
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Zheng Wei, Ph.D., Co-Founder and CEO, and Raúl Collazo, Ph.D., Global Head of Medical Affairs will participate in H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference in a fireside chat on Thursday, March 28, 2024 at 4:00 p.m. ET. Please see below for additional details about the event and how to request a one-on-one meeting with management.
2023-12-11 16:05:00 - GlobeNewsWire
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the top-line data...
2023-11-28 11:17:21 - Zacks Investment Research
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?
Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and DexCom (DXCM) have performed compared to their sector so far this year.
2023-11-20 16:41:00 - GlobeNewsWire
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will announce topline results from the Stage 2 (maintenance period) of its China pivotal trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) on Tuesday, November 21, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a...
2023-11-06 11:18:43 - Zacks Investment Research
Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year?
Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.
2023-10-20 11:18:53 - Zacks Investment Research
Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year?
Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and Haemonetics (HAE) have performed compared to their sector so far this year.
2023-09-15 13:32:22 - Zacks Investment Research
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock?
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-08-24 18:21:00 - GlobeNewsWire
Connect Biopharma to Participate in Upcoming September Investor Conferences
SAN DIEGO and TAICANG, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Connect Biopharma's management team will participate at the following upcoming investor conferences:
2023-03-20 10:41:19 - Pulse2
CNTB Stock Surges Over 20%: Explanation
The stock price of Connect Biopharma Holdings Ltd (NASDAQ: CNTB) surged by over 20% intraday today. This is why.